Every healthcare CFO’s inbox now has an AI-in-RCM pitch in it. The promises are consistent: lower denial rates, faster collections, leaner overhead. What’s inconsistent is the due diligence behind the decision to buy.
Most of these deals are still evaluated like traditional software purchases: features, price, timeline. That framework misses what actually determines whether an AI investment pays off or becomes a costly write-off eighteen months later: data readiness, workforce redesign, and governance exposure that never show up on a vendor’s feature sheet.
Before approving a budget for AI in revenue cycle management, CFOs should be asking seven specific questions, and most vendors are hoping they won’t.
1. What problem are we actually trying to solve?
Before evaluating any AI vendor, this question needs a specific answer, and “reduce costs” or “improve efficiency” isn’t specific enough. RCM has distinct pain points, and each one calls for a different type of AI solution:
• Denials management: Is the issue upfront claim accuracy, or is it appeals and resubmission volume?
• Coding accuracy: Are errors concentrated in specific specialties or payer types?
• Staffing shortages: Is the gap in claims processing capacity, or in the specialized judgment needed for complex cases?
• Prior authorization: Is the bottleneck submission volume, or turnaround time from payers?
• Patient collections: Is the friction in communication, payment options, or upfront cost estimation?
These are different problems with different root causes, and AI vendors tend to pitch broad platforms that claim to address all of them. A CFO who can’t name the specific workflow and its underlying cause will struggle to evaluate whether a vendor’s claims are realistic for their organization, or to hold that vendor accountable to a specific outcome after implementation.
The practical step: Before any vendor conversation, pull current performance data on the workflow in question: denial rate by category, days in A/R, cost to collect, and use that baseline to define what “success” would concretely look like. Without that baseline, ROI claims from any vendor are unverifiable.
2. Which RCM workflows will generate the fastest ROI?
Once the target problem is defined, the next question is sequencing: where should AI be deployed first? The instinct is often to start with the most painful or complex workflow, but that’s usually the wrong place to prove value.
High-volume, repetitive, rules-based processes are the better starting point:
• Claims scrubbing: Catching errors before submission, at scale, with clear pass/fail criteria.
• Eligibility verification: High transaction volume, low judgment complexity, fast feedback loop.
• Routine coding assistance: For common, well-documented procedures rather than edge cases.
These workflows let AI demonstrate measurable results quickly, with lower implementation risk, which does two things: It builds internal confidence (and vendor accountability) before committing to harder problems and it generates the operational data needed to evaluate whether a vendor’s model actually performs as advertised in your environment.
Complex judgment-heavy workflows, appeals strategy, payer negotiation, denial root-cause analysis, are where AI adds real value long-term, but they’re harder to validate quickly and carry more risk if the model underperforms. Save those for phase two, once the vendor relationship and internal processes have proven out on simpler ground.
The practical step: Ask vendors to show performance data specifically on high-volume rules-based workflows before considering pilots on your most complex processes. A vendor that leads with complex use cases before proving out simple ones is a signal worth noting.
3. Can our data support effective AI?
AI models are only as good as the data they’re trained on and fed in production, and healthcare data has structural problems that don’t show up in a vendor demo. Before committing budget, a clear-eyed assessment of data readiness is needed across three dimensions:
• Quality: Are claims and billing records complete, consistently coded, and free of the manual entry errors that accumulate in legacy systems? A model trained on inconsistent historical data will replicate those inconsistencies at scale.
• Governance: Who owns data quality across EHR, billing, and claims systems? Is there a clear process for correcting errors the AI surfaces, or will flagged issues sit unresolved because no one’s accountable for fixing the underlying data?
• Interoperability: Can the AI actually access the data it needs across systems, or does it only see a fraction of the picture because EHR, billing platform, and claims clearinghouse don’t talk to each other cleanly?
A lot of RCM AI pilots quietly underperform right here: not because the model is bad, but because the data feeding it is fragmented or inconsistent, and no one diagnosed that before signing the contract. Vendors rarely lead with this question because the answer is usually “it depends on your systems,” which doesn’t help them close a deal.
The practical step: Run a data audit: sample size, completeness, consistency across systems, on the specific workflow targeted in question one, before the vendor eval process, not after signing. If the audit reveals gaps, that’s a cost and timeline input for the business case, not a reason to abandon the project. For organizations without internal bandwidth to run this audit, experienced RCM outsourcing partners, such as OutsourcerRCM, can perform this diagnostic work independently of any AI vendor, which also avoids the conflict of interest inherent in a vendor auditing its own prerequisites.
4. How will AI integrate with our existing RCM and EHR systems?
A model that performs well in isolation is worthless if it can’t function inside the actual technology stack running the revenue cycle. This question moves past data readiness into the practical mechanics of deployment:
• Compatibility: Does the AI tool have proven integrations with your specific EHR and billing platforms, or is this a custom build the vendor is scoping for the first time on your account?
• Implementation effort: What’s the realistic timeline, including IT resources, testing, and staff training, not the vendor’s best-case estimate?
• Vendor support: What happens when the integration breaks, or when your EHR vendor pushes an update that affects the AI tool’s data access? Is there a defined support SLA, or is this an unsupported gray area?
Generic vendor case studies deserve real skepticism here. A successful deployment at a health system running Epic doesn’t guarantee the same result at a system running Cerner, or a smaller practice management system entirely. Integration complexity is specific to your environment, not the vendor’s.
The practical step: Ask for references from organizations running the same EHR/billing stack, not just any reference client. Request a realistic implementation timeline in writing, including internal resource requirements, and build in contingency, since first-time integrations at a new site rarely go exactly to plan.
5. How will we measure success?
Vague success metrics are how AI pilots quietly become permanent without ever proving their value, or get killed prematurely because no one agreed in advance what “working” looks like. Before implementation, specific, pre-agreed KPIs need to be tied to the problem defined in question one:
• Denial rate: By category and payer, not just an aggregate number that can mask uneven performance.
• Days in A/R: Tracked before and after, isolated to the workflow the AI is actually touching.
• Clean claim rate: The percentage of claims accepted on first submission, a direct signal of upfront accuracy improvements.
• Cost to collect: Total RCM operating cost as a percentage of revenue collected, capturing whether efficiency gains are real or just shifted elsewhere.
• Net collection rate: The ultimate test of whether AI is improving actual dollars collected, not just process metrics that look good on a dashboard.
The discipline here is defining these targets before deployment, with a clear baseline from the data pulled in question one, and a specific timeframe for evaluation. Without that, any outcome can be spun as a win; a vendor will always find a metric that moved in the right direction, even if the metric that matters didn’t.
The practical step: Set numeric thresholds in writing before the pilot starts: for example, “reduce denial rate in category X from Y% to Z% within six months,” and agree with the vendor upfront on what happens if those thresholds aren’t met.
6. What governance, compliance, and security controls are required?
AI in RCM touches protected health information at scale, which means governance isn’t a checkbox exercise; it’s a direct financial and legal exposure if handled poorly. Clear answers are needed in four areas before signing:
• HIPAA and PHI protection: How does the vendor handle PHI in training data, model outputs, and any third-party infrastructure (cloud hosting, subprocessors)? Get this in writing, not as a verbal assurance.
• Vendor risk: What’s the vendor’s own security posture, breach history, and financial stability? An AI vendor that fails or gets acquired mid-contract creates real operational risk for a workflow now dependent on their tool.
• Auditability: Can the organization trace how the AI arrived at a specific decision (a denial flag, a coding suggestion) if that decision is challenged internally, by a payer, or in an audit? “The model said so” is not a defensible answer to a compliance question.
• Human oversight: Is there a defined process for staff to review, override, and correct AI outputs, or does the tool operate as a black box that staff are expected to trust by default?
This is the question most likely to get rushed in a budget cycle, because governance doesn’t show up on an ROI spreadsheet the way denial-rate improvements do. But a compliance failure or data breach tied to an ungoverned AI tool costs far more than the tool ever saved.
The practical step: Require a written data handling and security addendum as a condition of contract, reviewed by compliance and legal before finance signs off, not after implementation reveals gaps.
7. How will AI change our workforce and operating model?
This is the question with the most long-term impact, and the one most often treated as an afterthought. AI in RCM doesn’t just automate tasks; it changes what the RCM team is for. Getting this wrong creates either quiet resistance that undermines adoption, or a workforce plan that doesn’t match what the technology actually requires.
• Augmentation vs. replacement: Most effective RCM AI deployments shift staff away from repetitive processing (data entry, routine claim submission) and toward the judgment work AI can’t do: complex appeals, payer relationship management, root-cause denial analysis. Framing this internally as elimination rather than reallocation breeds resistance before the tool even launches.
• Training: Staff need to learn not just how to use the new tool, but how to evaluate its outputs critically: when to trust an AI recommendation and when to override it. That’s a different skill set than the one most RCM teams were hired for.
• Change management: Who owns communicating this shift to staff, and how early? Teams that hear about AI adoption from a vendor demo rather than their own leadership tend to disengage or actively work around the tool.
• Redefining roles: Job descriptions, performance metrics, and career paths in RCM need to reflect the judgment-heavy work that remains, not the task list that existed before automation.
The organizations that get the most value from RCM AI are the ones that treat workforce redesign as part of the implementation plan, not a downstream HR problem to solve later. The ones that struggle are usually the ones that bought the technology and assumed the org chart would sort itself out.
The practical step: Build a workforce transition plan alongside the technology implementation plan, not after go-live, including which roles shift, what retraining looks like, and how success is communicated internally before the AI tool goes live.
The bottom line
These seven questions share a common thread: They treat AI adoption in RCM as a system-level financial and operational commitment, not a software purchase. A vendor demo can show what a tool does. It can’t show whether it will work inside your specific data environment, integrate with your existing systems, hit the financial targets your board expects, or land well with the team that has to use it every day.
CFOs who ask these questions before signing aren’t slowing down innovation; they’re the ones who avoid the two most common outcomes of rushed AI adoption in healthcare finance: pilots that quietly stall because no one defined success upfront, and implementations that hit denial-rate or A/R targets on paper while creating compliance exposure or staff attrition underneath. The RCM leaders getting real value from AI right now are the ones asking these questions early, not the ones moving fastest.
Photo: sdecoret, Getty Images
Purnendu Bala is a market analyst and AI researcher who writes about AI adoption in healthcare, with a focus on its safe, responsible, and business-driven implementation. He is currently associated with OutsourceRCM, a U.S.-focused medical billing and revenue cycle management (RCM) services company.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
